STAT3 and cancer: Given that STAT3 inhibitors, like C188‐9, have been gauged in primary stage clinical trials for advanced‐stage cancers (NCT03195699),28, 33, 34 our data support that combining STAT3 inhibition with oncolytic NDV may represent a particularly promising approach to optimize NDV‐based virotherapy in the clinical setting.